Hepatitis C virus (HCV) infection is associated with tremendous morbidity and mortality due to liver complications. HCV infection is also associated with many extrahepatic manifestations including cardiovascular diseases, glucose metabolism impairment, cryoglobulinemia vasculitis, B cell non-Hodgkin lymphoma and chronic kidney disease (CKD). Many studies have shown a strong association between HCV and CKD, by reporting (i) an increased prevalence of HCV infection in patients on haemodialysis, (ii) an increased incidence of CKD and proteinuria in HCV-infected patients, and (iii) the development of membranoproliferative glomerulonephritis secondary to HCV-induced cryoglobulinemia vasculitis. HCV seropositivity is found to be associated with an increased relative risk for all-cause and cardiovascular mortality in the dialysis population. HCV seropositivity is linked to lower patient and graft survival after kidney transplantation. Such poor HCV-associated prognosis should have encouraged clinicians to treat HCV in CKD patients. However, due to frequent side effects and the poor efficacy of interferon-based treatments, very few HCV dialysis patients have received HCV medications until now. The emergence of new direct acting, interferon-free antiviral treatment, leading to HCV cure in most cases with a satisfactory safety profile, will shortly modify the management of HCV infection in CKD patients. In patients with a glomerular filtration rate (GFR) >30 ml/min, the choice of DM is not restricted. In those with a GFR <30 and >15 ml/min, only paritaprevir/ritonavir/ombitasvir/dasabuvir or a grazoprevir plus elbasvir regimen are approved. In patients with end stage renal disease (GFR <15 ml/min or dialysis), current data only allows for the use of a grazoprevir plus elbasvir combination. No doubt these data will be modified in the future with the advent of new studies including larger cohorts of HCV patients with renal impairment. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Hepatitis C virus infection and chronic kidney disease: Time for reappraisal / Cacoub, P; Desbois, Ac; Isnard Bagnis, C; Rocatello, D; Ferri, Clodoveo. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 65:1(2016), pp. S82-S94. [10.1016/j.jhep.2016.06.011]

Hepatitis C virus infection and chronic kidney disease: Time for reappraisal

FERRI, Clodoveo
2016

Abstract

Hepatitis C virus (HCV) infection is associated with tremendous morbidity and mortality due to liver complications. HCV infection is also associated with many extrahepatic manifestations including cardiovascular diseases, glucose metabolism impairment, cryoglobulinemia vasculitis, B cell non-Hodgkin lymphoma and chronic kidney disease (CKD). Many studies have shown a strong association between HCV and CKD, by reporting (i) an increased prevalence of HCV infection in patients on haemodialysis, (ii) an increased incidence of CKD and proteinuria in HCV-infected patients, and (iii) the development of membranoproliferative glomerulonephritis secondary to HCV-induced cryoglobulinemia vasculitis. HCV seropositivity is found to be associated with an increased relative risk for all-cause and cardiovascular mortality in the dialysis population. HCV seropositivity is linked to lower patient and graft survival after kidney transplantation. Such poor HCV-associated prognosis should have encouraged clinicians to treat HCV in CKD patients. However, due to frequent side effects and the poor efficacy of interferon-based treatments, very few HCV dialysis patients have received HCV medications until now. The emergence of new direct acting, interferon-free antiviral treatment, leading to HCV cure in most cases with a satisfactory safety profile, will shortly modify the management of HCV infection in CKD patients. In patients with a glomerular filtration rate (GFR) >30 ml/min, the choice of DM is not restricted. In those with a GFR <30 and >15 ml/min, only paritaprevir/ritonavir/ombitasvir/dasabuvir or a grazoprevir plus elbasvir regimen are approved. In patients with end stage renal disease (GFR <15 ml/min or dialysis), current data only allows for the use of a grazoprevir plus elbasvir combination. No doubt these data will be modified in the future with the advent of new studies including larger cohorts of HCV patients with renal impairment. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
2016
65
1
S82
S94
Hepatitis C virus infection and chronic kidney disease: Time for reappraisal / Cacoub, P; Desbois, Ac; Isnard Bagnis, C; Rocatello, D; Ferri, Clodoveo. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 65:1(2016), pp. S82-S94. [10.1016/j.jhep.2016.06.011]
Cacoub, P; Desbois, Ac; Isnard Bagnis, C; Rocatello, D; Ferri, Clodoveo
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0168827816302732-main.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 969.92 kB
Formato Adobe PDF
969.92 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1138708
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 78
  • ???jsp.display-item.citation.isi??? 68
social impact